Price: $399.99
Duration: 30 Months of Access
Deliverables: 12.0 Hours of AAPA Category 1 Self-Assessment Pharmacology CME Credit
Finding high-quality, relevant pharmacology education that meets specific state and national requirements can be a challenge for the busy physician assistant. While general CME is abundant, targeted pharmacology credit often requires digging through fragmented resources. At CME Review Courses, we provide an efficient, consolidated solution designed by PAs for PAs.
Whether you are preparing for the PANRE or meeting a state mandate, understanding the nuances of pharmacology credit is essential for maintaining your license and certification.
1. State-Specific Prescribing Mandates (The Florida Example)
State licensing boards frequently impose requirements that exceed the baseline NCCPA certification standards. Florida is a primary example of a state with rigorous pharmacology and prescribing mandates. PAs in Florida who hold prescribing authority are required to complete specific hours in controlled substance prescribing and medical errors during every biennial renewal period.
These requirements often specify that the credit must be AAPA Category 1 and focused on the pharmacology of controlled substances or opioid stewardship. Our Pharmacology Review Course is designed to satisfy these topic-specific needs, ensuring you remain compliant with state law while simultaneously earning credit toward your national recertification.
2. The MATE Act and DEA Requirements
As of June 2023, the Medication Access and Training Expansion (MATE) Act requires all DEA-registered practitioners to complete a one-time 8-hour training requirement on the treatment and management of patients with opioid or other substance use disorders.
This is not a suggestion; it is a federal requirement for renewing your DEA registration. When selecting a pharmacology course, PAs should look for content that addresses these specific competencies. Our pharmacology modules provide deep dives into medication-assisted treatment (MAT) and safe prescribing practices, helping you fulfill these critical federal obligations.
3. Pharmacology in the NCCPA Blueprint
The NCCPA Blueprint for the PANCE and PANRE integrates pharmacology across almost every organ system. It is not enough to simply know the medications; you must understand the pharmacokinetics and pharmacodynamics within the context of specific disease states.
For instance, Cardiology accounts for a significant portion of the NCCPA Blueprint. You are expected to know the difference between dihydropyridine and non-dihydropyridine calcium channel blockers, the indications for direct oral anticoagulants (DOACs), and the nuances of anti-arrhythmic management. Our course structure follows the NCCPA Blueprint, ensuring that your study time is spent on the topics most likely to appear on your exam.
4. The Self-Assessment Credit Multiplier
One of the most efficient ways to manage your 100-hour CME cycle is to utilize Self-Assessment CME. The NCCPA provides a "bonus" for these credits: when you log AAPA Category 1 Self-Assessment CME, the NCCPA applies a 50% multiplier.
This means our Pharmacology Review Course, which offers 12.0 hours of AAPA Category 1 Self-Assessment credit, actually counts as 18.0 credits toward your 100-hour requirement when logged with the NCCPA. This efficiency allows you to satisfy state pharmacology mandates while making faster progress toward your total credit goal.
5. Practical Prescribing Competency
Beyond the requirements, there is the matter of clinical safety. Medical errors related to pharmacology are among the most common adverse events in clinical practice. A structured review of pharmacology helps mitigate these risks by reinforcing knowledge of drug-drug interactions, contraindications, and dosing adjustments for renal or hepatic impairment.
Our course content was written by experienced PAs who understand the daily clinical challenges of prescribing. We focus on high-yield, practical information that you can apply at the bedside immediately, moving beyond rote memorization to true clinical mastery.
Efficient Integration with PANRE Preparation
While our Pharmacology Review Course provides 12 hours of specialized credit, many PAs choose to pair it with our comprehensive PANRE Review Course.
The PANRE Review Course offers 100 hours of AAPA Category 1 CME credit (which equates to 150 NCCPA credits with the multiplier) and covers the entire spectrum of the NCCPA Blueprint. By using these courses in tandem, you can ensure that your pharmacology knowledge is robust while you simultaneously prepare for the broad range of topics found on the recertification exam.
Clinical Vignette Assessment
Scenario 1
Your patient is a 64-year-old male with a history of hypertension, Type 2 Diabetes, and chronic kidney disease (Stage 3). His current medications include lisinopril, metformin, and atorvastatin. His BP today is 152/94 mmHg, and his latest labs show a serum potassium of 5.1 mEq/L and a GFR of 42 mL/min/1.73m². You decide to add a second agent for blood pressure control. Which of the following is the most appropriate next step?
A) Add spironolactone
B) Add amlodipine
C) Increase lisinopril dose
D) Add hydrochlorothiazide
Explanation:
Correct Answer: B) Add amlodipine.
In a patient with Stage 3 CKD and a potassium level already at the high end of normal (5.1 mEq/L), adding a calcium channel blocker like amlodipine is the safest and most effective choice. Amlodipine does not affect potassium levels and is highly effective in diabetic patients. Spironolactone (A) is contraindicated here due to the high risk of hyperkalemia in a patient already on an ACE inhibitor with impaired renal function. Increasing the lisinopril (C) would further increase the risk of hyperkalemia and acute kidney injury. Hydrochlorothiazide (D) loses significant efficacy when the GFR is below 30-40 mL/min and would be less effective than amlodipine in this scenario.
Scenario 2
Your patient is a 45-year-old female presenting with symptoms of major depressive disorder. She also reports a 10-year history of smoking 1 pack of cigarettes per day and has expressed a desire to quit. Which of the following medications would be the best choice to address both her depression and her smoking cessation?
A) Fluoxetine
B) Bupropion
C) Varenicline
D) Amitriptyline
Explanation:
Correct Answer: B) Bupropion.
Bupropion (Wellbutrin/Zyban) is uniquely indicated for both the treatment of major depressive disorder and as an aid for smoking cessation. It works by inhibiting the reuptake of norepinephrine and dopamine. Fluoxetine (A) is an SSRI effective for depression but has no specific role in smoking cessation. Varenicline (C) is excellent for smoking cessation but is not an antidepressant. Amitriptyline (D) is a tricyclic antidepressant that is rarely used as a first-line agent due to its side effect profile and toxicity in overdose, and it has no role in smoking cessation.
Take the Next Step in Your Education
Don't let your recertification or state licensure requirements become a source of stress. Our courses are designed to provide the most efficient path to earning your AAPA Category 1 CME.
Invest in the Pharmacology Review Course or maximize your credits with our full PANRE Review Course today. Gain 30 months of access and start earning your credits on your own schedule.